Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14631107 | 0.78 | KMT2A (0.41) | SLC6A2SLC6A4MEN1ALDH1A1KMT2A | |
| SCHEMBL8091604 | 0.74 | MEN1 (0.44) | SLC6A2SLC6A4MEN1ALDH1A1KMT2A | |
| SCHEMBL532533 | 0.70 | KDM4E (0.46) | SLC6A2SLC6A4MEN1ALDH1A1KMT2A | |
| SCHEMBL9727566 | 0.69 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL9797411 | 0.69 | SLC6A2 (0.54) | SLC6A2SLC6A4ALDH1A1SLC6A3KCNH2 | |
| SCHEMBL3485687 | 0.68 | ALDH1A1 (0.71) | SLC6A2SLC6A4MEN1ALDH1A1KMT2A | |
| SCHEMBL3839948 | 0.68 | KMT2A (0.41) | SLC6A2SLC6A4MEN1ALDH1A1KMT2A | |
| SCHEMBL6205468 | 0.68 | SLC6A4 (0.42) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL6256044 | 0.68 | HTR2A (0.46) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL7603869 | 0.68 | SLC6A2 (0.61) | SLC6A2SLC6A4MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000174-B2 | 4-phenylsulfonamidopiperidines as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | EURO-CELTIQUE S.A. (LU) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | CACNA1A, CACNA1E, CACNA1B | SLC6A2 226/4885SLC6A4 151/4885MEN1 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.